Literature DB >> 32696443

The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.

Matteo Paganini1, Gerardo Bosco2, Filippo A G Perozzo3, Eva Kohlscheen3, Regina Sonda3, Franco Bassetto3, Giacomo Garetto4, Enrico M Camporesi5, Stephen R Thom6.   

Abstract

The recent coronavirus disease 2019 (COVID-19) pandemic produced high and excessive demands for hospitalizations and equipment with depletion of critical care resources. The results of these extreme therapeutic efforts have been sobering. Further, we are months away from a robust vaccination effort, and current therapies provide limited clinical relief. Therefore, several empirical oxygenation support initiatives have been initiated with intermittent hyperbaric oxygen (HBO) therapy to overcome the unrelenting and progressive hypoxemia during maximum ventilator support in intubated patients, despite high FiO2. Overall, few patients have been successfully treated in different locations across the globe. More recently, less severe patients at the edge of impending hypoxemia were exposed to HBO preventing intubation and obtaining the rapid resolution of symptoms. The few case descriptions indicate large variability in protocols and exposure frequency. This summary illustrates the biological mechanisms of action of increased O2 pressure, hoping to clarify more appropriate protocols and more useful application of HBO in COVID-19 treatment.

Entities:  

Keywords:  COVID-19; Hyperbaric oxygen therapy; Hypoxemia; Inflammation

Mesh:

Substances:

Year:  2021        PMID: 32696443     DOI: 10.1007/5584_2020_568

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  60 in total

1.  Thioredoxin reductase linked to cytoskeleton by focal adhesion kinase reverses actin S-nitrosylation and restores neutrophil β(2) integrin function.

Authors:  Stephen R Thom; Veena M Bhopale; Tatyana N Milovanova; Ming Yang; Marina Bogush
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

2.  Stem cell mobilization by hyperbaric oxygen.

Authors:  Stephen R Thom; Veena M Bhopale; Omaida C Velazquez; Lee J Goldstein; Lynne H Thom; Donald G Buerk
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-18       Impact factor: 4.733

3.  Effects of a standard hyperbaric oxygen treatment protocol on pulmonary function.

Authors:  E Thorsen; L Aanderud; T B Aasen
Journal:  Eur Respir J       Date:  1998-12       Impact factor: 16.671

Review 4.  Pulmonary oxygen toxicity: a review.

Authors:  J M Clark; C J Lambertsen
Journal:  Pharmacol Rev       Date:  1971-06       Impact factor: 25.468

Review 5.  Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation.

Authors:  E Peterhans
Journal:  J Nutr       Date:  1997-05       Impact factor: 4.798

6.  Induction of interleukin-1 beta (IL-1β) is a critical component of lung inflammation during influenza A (H1N1) virus infection.

Authors:  Kwang Seok Kim; Hyemin Jung; In Kyung Shin; Bo-Ra Choi; Dong Ho Kim
Journal:  J Med Virol       Date:  2015-03-19       Impact factor: 2.327

Review 7.  The role of oxidative stress in HIV disease.

Authors:  G W Pace; C D Leaf
Journal:  Free Radic Biol Med       Date:  1995-10       Impact factor: 7.376

8.  Hyperbaric oxygen therapy effects on pulmonary functions: a prospective cohort study.

Authors:  Amir Hadanny; Tal Zubari; Liat Tamir-Adler; Yair Bechor; Gregory Fishlev; Erez Lang; Nir Polak; Jacob Bergan; Mony Friedman; Shai Efrati
Journal:  BMC Pulm Med       Date:  2019-08-13       Impact factor: 3.317

9.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

10.  Hyperbaric Oxygen Therapy Improves the Osteogenic and Vasculogenic Properties of Mesenchymal Stem Cells in the Presence of Inflammation In Vitro.

Authors:  Chiara Gardin; Gerardo Bosco; Letizia Ferroni; Silvia Quartesan; Alex Rizzato; Marco Tatullo; Barbara Zavan
Journal:  Int J Mol Sci       Date:  2020-02-20       Impact factor: 5.923

View more
  5 in total

1.  Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial.

Authors:  Abu Taiub Mohammed Mohiuddin Chowdhury; Aktar Kamal; Kafil Uddin Abbas; Shubhashis Talukder; Md Rezaul Karim; Md Ahsan Ali; Md Nuruzzaman; Yarui Li; Shuixiang He
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

2.  Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19.

Authors:  Kuaikuai Duan; Enrico Premi; Andrea Pilotto; Viviana Cristillo; Alberto Benussi; Ilenia Libri; Marcello Giunta; H Jeremy Bockholt; Jingyu Liu; Riccardo Campora; Alessandro Pezzini; Roberto Gasparotti; Mauro Magoni; Alessandro Padovani; Vince D Calhoun
Journal:  Neurobiol Stress       Date:  2021-04-13

Review 3.  Hyperbaric Oxygen Treatment-From Mechanisms to Cognitive Improvement.

Authors:  Irit Gottfried; Nofar Schottlender; Uri Ashery
Journal:  Biomolecules       Date:  2021-10-15

Review 4.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

Review 5.  From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.

Authors:  Paulo Ricardo Criado; Hélio Amante Miot; Thais Prota Hussein Pincelli; Alexandre Todorovic Fabro
Journal:  Dermatol Ther       Date:  2020-11-30       Impact factor: 3.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.